Portal de investigação
Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Sousa, C
- Reis, JP
- Cruz Martins, N
- Moura, CS
- Guimaraes, S
- Justino, A
- Pina, MJ
- Magalhaes, A
- Queiroga, H
- Marques, JA
- Costa, JL
Unidades de investigação
Abstract
Introduction: Cell-free DNA (cfDNA) analysis offers a non-invasive method to identify sensitising and resistance mutations in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Next-generation sequencing (NGS) of circulating free DNA (cfDNA) is a valuable tool for mutations detection and disease ' s clonal monitoring. Material and methods: An amplicon-based targeted gene NGS panel was used to analyse 101 plasma samples of advanced non-small cell lung cancer (NSCLC) patients with known oncogenic mutations, mostly EGFR mutations, serially collected at different clinically relevant time points of the disease. Results: The variant allelic frequency (VAF) monitoring in consecutive plasma samples demonstrated different molecular response and progression patterns. The decrease in or the clearance of the mutant alleles was associated with response and the increase in or the emergence of novel alterations with progression. At the best response, the median VAF was 0% (0.0% to 3.62%), lower than that at baseline, with a median of 0.53% (0.0% to 9.9%) (p = 0.004). At progression, the VAF was significantly higher (median 4.67; range: 0.0-36.9%) than that observed at the best response (p = 0.001) and baseline (p = 0.006). These variations anticipated radiographic changes in most cases, with a median time of 0.86 months. Overall, the VAF evolution of different oncogenic mutations predicts clinical outcomes. Conclusion: The targeted NGS of circulating tumour DNA (ctDNA) has clinical utility to monitor treatment response in patients with advanced lung adenocarcinoma.
Dados da publicação
- ISSN/ISSNe:
- 2073-4409, 2073-4409
- Tipo:
- Article
- Páginas:
- 1912-
- Link para outro recurso:
- www.scopus.com
Cells Multidisciplinary Digital Publishing Institute (MDPI)
Citações Recebidas na Web of Science: 10
Citações Recebidas na Scopus: 13
Documentos
- Não há documentos
Filiações
Keywords
- lung cancer; adenocarcinoma; liquid biopsy; cell-free DNA; tumour-free DNA; next-generation sequencing; clinical outcomes
Campos de estudo
Financiamento
Proyectos asociados
Doença do Refluxo Gastro-esofágico e Doença Pulmonar
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (Refluxo Gastro-esofágic) . 2020
A importância do diagnóstico na Fibrose Pulmonar Idiopática
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (FPI) . 2020
Imunoterapia no cancro do pulmão: PD-L1, biomarcador preditivo?
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico . 2020
Citar a publicação
Fernandes M,Sousa C,Reis JP,Cruz N,Moura CS,Guimaraes S,Justino A,Pina MJ,Magalhaes A,Queiroga H,Marques JA,Machado J,Costa JL,Hespanhol V. Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. Cells. 2021. 10. (8):p. 1912-1912. IF:7,666. (2).
